Fig 1: Expression of L1CAM is a prognostic marker in curettage samples, blood samples and hysterectomy samples of endometrial cancer patients. High expression of L1CAM in curettage samples was significantly associated with poor outcome in the whole patient population (A) and in the subgroup of patients with low-risk histology in curettage (B). In plasma from endometrial cancer patients, high level of L1CAM was predictive of poor outcome in both the whole patient population (C) and the subgroup of patients with low-risk histology in curettage (D). High expression of L1CAM in hysterectomy samples is significantly associated with poor survival in both the whole population (E) and the subgroup with stage 1 endometrioid endometrial cancer (F). *Curettage histological risk classification, low risk (benign, hyperplasia or endometrioid grades 1–2) or high risk (non-endometrioid or endometrioid grade 3). Number in brackets: number of patients in the group/number of events in the group.